|
1
|
Saginala K and Barsouk A, Aluru JS, Rawla
P, Padala SA and Barsouk A: Epidemiology of bladder cancer. Med Sci
(Basel). 8:152020.PubMed/NCBI
|
|
2
|
Bellmunt J, Mottet N and De Santis M:
Urothelial carcinoma management in elderly or unfit patients. EJC
Suppl. 14:1–20. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galsky MD, Pal SK, Chowdhury S, Harshman
LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, et
al: Comparative effectiveness of gemcitabine plus cisplatin versus
methotrexate, vinblastine, doxorubicin, plus cisplatin as
neoadjuvant therapy for muscle-invasive bladder cancer. Cancer.
121:2586–2593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee FC, Harris W, Cheng HH, Shenoi J, Zhao
S, Wang J, Champion T, Izard J, Gore JL, Porter M, et al:
Pathologic response rates of gemcitabine/cisplatin versus
methotrexate/vinblastine/adriamycin/cisplatin neoadjuvant
chemotherapy for muscle invasive urothelial bladder cancer. Adv
Urol. 2013:3171902013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Powles T, Park SH, Voog E, Caserta C,
Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén
A, et al: Avelumab maintenance therapy for advanced or metastatic
urothelial carcinoma. N Engl J Med. 383:1218–1230. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenberg JE, Hoffman-Censits J, Powles T,
van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH,
Balmanoukian A, Loriot Y, et al: Atezolizumab in patients with
locally advanced and metastatic urothelial carcinoma who have
progressed following treatment with platinum-based chemotherapy: A
single-arm, multicentre, phase 2 trial. Lancet. 387:1909–1920.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Balar AV, Galsky MD, Rosenberg JE, Powles
T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J,
Perez-Gracia JL, et al: Atezolizumab as first-line treatment in
cisplatin-ineligible patients with locally advanced and metastatic
urothelial carcinoma: A single-arm, multicentre, phase 2 trial.
Lancet. 389:67–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Powles T, O'Donnell PH, Massard C, Arkenau
HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang
NJ, et al: Efficacy and safety of durvalumab in locally advanced or
metastatic urothelial carcinoma: Updated results from a phase 1/2
open-label study. JAMA Oncol. 3:e1724112017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Massard C, Gordon MS, Sharma S, Rafii S,
Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE,
et al: Safety and efficacy of durvalumab (MEDI4736), an
anti-programmed cell death ligand-1 immune checkpoint inhibitor, in
patients with advanced urothelial bladder cancer. J Clin Oncol.
34:3119–3125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sharma P, Retz M, Siefker-Radtke A, Baron
A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, et
al: Nivolumab in metastatic urothelial carcinoma after platinum
therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial.
Lancet Oncol. 18:312–322. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Balar AV, Castellano D, O'Donnell PH,
Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L,
et al: First-line pembrolizumab in cisplatin-ineligible patients
with locally advanced and unresectable or metastatic urothelial
cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study.
Lancet Oncol. 18:1483–1492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y,
Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK,
et al: Pembrolizumab as Second-Line Therapy for Advanced Urothelial
Carcinoma. N Engl J Med. 376:1015–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bednova O and Leyton JV: Targeted
molecular therapeutics for bladder cancer-a new option beyond the
mixed fortunes of immune checkpoint inhibitors? Int J Mol Sci.
21:72682020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
George AS, Fernandez CJ, Eapen D and
Pappachan JM: Organ-specific adverse events of immune checkpoint
inhibitor therapy, with special reference to endocrinopathies.
touchREV Endocrinol. 17:21–32. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Loriot Y, Necchi A, Park SH, Garcia-Donas
J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B,
Varlamov S, et al: Erdafitinib in locally advanced or metastatic
urothelial carcinoma. N Engl J Med. 381:338–348. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Powles T, Rosenberg JE, Sonpavde GP,
Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D,
Wu C, et al: Enfortumab vedotinin previously treated advanced
urothelial carcinoma. N Engl J Med. 384:1125–1135. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tagawa ST, Balar AV, Petrylak DP,
Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M,
Barthelemy P, et al: TROPHY-U-01: A phase II open-label study of
sacituzumab govitecanin patients with metastatic urothelial
carcinoma progressing after platinum-based chemotherapy and
checkpoint inhibitors. J Clin Oncol. 39:2474–2485. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zaman S, Jadid H, Denson AC and Gray JE:
Targeting Trop-2 in solid tumors: Future prospects. Onco Targets
Ther. 12:1781–1790. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guan H, Guo Z, Liang W, Li H, Wei G, Xu L,
Xiao H and Li Y: Trop2 enhances invasion of thyroid cancer by
inducing MMP2 through ERK and JNK pathways. BMC Cancer. 17:4862017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stoyanova T, Goldstein AS, Cai H, Drake
JM, Huang J and Witte ON: Regulated proteolysis of Trop2 drives
epithelial hyperplasia and stem cell self-renewal via β-catenin
signaling. Genes Dev. 26:2271–2285. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
El Sewedy T, Fornaro M and Alberti S:
Cloning of the murine Trop2 gene: conservation of a PIP2-binding
sequence in the cytoplasmic domain of Trop-2. Int J Cancer.
75:324–330. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goldenberg DM, Stein R and Sharkey RM: The
emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel
cancer target. Oncotarget. 9:28989–29006. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao W, Zhu H, Zhang S, Yong H, Wang W,
Zhou Y, Wang B, Wen J, Qiu Z, Ding G, et al: Trop2 is overexpressed
in gastric cancer and predicts poor prognosis. Oncotarget.
7:6136–6145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Union for international cancer control
(UICC), . TNM Classification of Malignant Tumours. 8th edition.
Brierley JD, Gospodarowicz MK and Wittekind Ch: Wiley-VCH;
Weinheim: 2016
|
|
25
|
WHO-Classification of urinary and male
genital tumours, . 5th Edition. Vol.8. Lyon (France): International
agency for Research on Cancer; 2022
|
|
26
|
Wucherpfennig S, Rose M, Maurer A,
Cassataro MA, Seillier L, Morsch R, Hammad E, Baldia PH, Ecke TH,
Vögeli TA, et al: Evaluation of therapeutic targets in histological
subtypes of bladder cancer. Int J Mol Sci. 22:115472021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dum D, Taherpour N, Menz A, Höflmayer D,
Völkel C, Hinsch A, Gorbokon N, Lennartz M, Hube-Magg C, Fraune C,
et al: Trophoblast cell surface antigen 2 expression in human
tumors: A tissue microarray study on 18,563 tumors. Pathobiology.
89:245–258. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tomiyama E, Fujita K, Nakano K, Kuwahara
K, Minami T, Kato T, Hatano K, Kawashima A, Uemura M, Takao T, et
al: Trop-2 in upper tract urothelial carcinoma. Curr Oncol.
29:3911–3921. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stepan LP, Trueblood ES, Hale K, Babcook
J, Borges L and Sutherland CL: Expression of Trop2 cell surface
glycoprotein in normal and tumor tissues: Potential implications as
a cancer therapeutic target. J Histochem Cytochem. 59:701–710.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu T, Liu Y, Bao X, Tian J, Liu Y and
Yang X: Overexpression of TROP2 predicts poor prognosis of patients
with cervical cancer and promotes the proliferation and invasion of
cervical cancer cells by regulating ERK signaling pathway. PLoS
One. 8:e758642013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, Yang G, Zhang R, Dong L, Chen H,
Bo J, Xue W and Huang Y: Curcumin inhibits cell proliferation and
motility via suppression of TROP2 in bladder cancer cells. Int J
Oncol. 53:515–526. 2018.PubMed/NCBI
|
|
32
|
Avellini C, Licini C, Lazzarini R, Gesuita
R, Guerra E, Tossetta G, Castellucci C, Giannubilo SR, Procopio A,
Alberti S, et al: The trophoblast cell surface antigen 2 and
miR-125b axis in urothelial bladder cancer. Oncotarget.
8:58642–58653. 2017. View Article : Google Scholar : PubMed/NCBI
|
